Menu

非布司他效果怎么样呢?

Author: Medicalhalo
Release time: 2025-10-19 11:44:20

Febuxostat (Febuxostat) is a xanthine oxidase (XO) inhibitor indicated for the long-term treatment of hyperuricemia with gout symptoms. Not recommended for the treatment of asymptomatic hyperuricemia. In 2009, febuxostat was approved for marketing in the United States. Its main ingredient is febuxostat, tablets, and oral use. From the development and use of the first acid-lowering drug for gout to today, treatment options for gout patients have been continuously developed and increased. Febuxostat is a safe and effective drug for the treatment of gout, and diet does not affect its acid-lowering effect.

How effective is febuxostat?

In a phase III clinical trial, the efficacy of allopurinol (300 mg/d) and febuxostat (80 and 120 mg/d) were compared. The study lasted for one year, and a total of 760 patients were included. All subjects were gout patients, and the sUA concentration before the trial was above 80 mg/L.

The treatment effect of the febuxostat (Febuxostat) group was relatively good. Compared with the allopurinol group, more patients reached the main trial efficacy index - the sUA concentration was measured below 60 mg/L in the last 3 months; after 52 weeks of treatment, Febuxostat (Febuxostat) failed to significantly reduce Tophi area (tophi is an aggregate of urate crystals unique to gout), but in the high-dose group early in the trial, this effect was more obvious; in each treatment group, patients with sUA concentration reaching the target (<60mg/L) were less likely to have gout attacks again, and their tophi area was more significantly reduced.

Febuxostat (Febuxostat) has a significant effect in the treatment of gout, and as a new drug, Febuxostat has a more powerful and long-lasting effect in reducing uric acid, making it a good choice for gout patients.

The above is an introduction to the therapeutic effects of febuxostat. Currently, febuxostat has been approved for marketing in my country. Patients can buy it without traveling overseas. If you have other questions, you can also consult the medical companion and travel service for answers.

[ 免责声明 ]  本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。